# NCT04254978 (NCT04254978)

> Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04254978
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
- Conditions: Essential Thrombocythemia
- Interventions: Bomedemstat
- Enrollment: 73
- Primary outcome: Number of Participants Who Experienced an Adverse Event (AE)
- Primary outcome: Number of Participants Who Discontinued Study Treatment Due to an AE
- Primary outcome: Percentage of Participants With Platelet Count ≤400 k/μL at Day 169

## Indexed commentary on NCT04254978 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04254978